ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, hypermethylation profile of HOXA4 gene also could be considered as an epigenetic biomarker, in addition to the BCR-ABL gene mutations analysis, for prediction of response to IM treatment among CML patients.